PROVEN Skincare Announces International Expansion; Personalized, Adaptive, and AI-Backed Skincare Products Now Available in the European Union and the United Kingdom
19.7.2022 11:05:00 EEST | Business Wire | Press release
PROVEN, the expert in personalized skincare, today announced its international expansion into the European Union and the United Kingdom. Products are currently available to purchase. This is PROVEN’s first international expansion since it launched in Canada in July 2021. The PROVEN team made the decision to expand across the Atlantic due to the global demand for personalized skincare solutions. This expansion comes after a period of extraordinary growth for the company, which includes the launch of its first new product since 2019, the Eye Cream Duo, and having been granted a groundbreaking patent that protects PROVEN’s use of personalization in skincare.
Since its founding in 2017 and launch in 2019, PROVEN Skincare has grown rapidly to become the leading skincare personalization brand. The company has launched five products personalized to customers’ unique needs, received the 2018 MIT Artificial Intelligence Technology Award, was awarded Best Use of Technology at the 2022 Glossy Beauty Awards for its proprietary Skin Genome Project™, and reached more than $30 million in revenue in just three years.
“I am incredibly proud to bring PROVEN’s personalized, data and AI-backed products to the people of the European Union and the United Kingdom,” said PROVEN co-founder and CEO Ming S. Zhao. “Too many consumers still rely on one-size-fits-all skincare products that do not take into account their unique concerns and needs. PROVEN provides personalized, adaptive, effective skincare solutions that take into account a person's skin, life, and environment. The entire PROVEN team is thrilled to enter these new markets and provide people with skincare solutions as unique as they are.”
In order to provide personalized skincare to customers across the European Union and the United Kingdom, the PROVEN team gathered extensive environmental data about the region and executed a major tech build to incorporate it into PROVEN's existing AI. Integrating local environmental conditions into the skincare formulas is essential for effective skincare products.
PROVEN was founded in 2017 by Ming Zhao and Dr. Amy Yuan and launched in 2019. Ming was in the midst of a career in private equity, working long hours when she began to notice the quality of her skin was suffering. She embarked on a personal mission to find products to solve her problems but found that most were expensive, didn’t work consistently, and the trial and error of trying to find something that worked was time-consuming.
She brought this up with her friend Amy, who just so happened to be a Computational Physicist at Stanford, who was having her own skin challenges. Recognizing that the beauty industry lacked a brand that offered personalized and effective solutions, the two joined forces to create a holistic, personalized approach to skincare that is completely backed by data. The result was PROVEN, which harnesses the power of big data and AI to create personalized skincare products.
PROVEN creates simple, personalized, and clinically proven skincare products at scale thanks to its proprietary Skin Genome Project™ — the largest beauty database on earth. The Skin Genome Project™ takes the following data into account in order to craft personalized products for consumers:
- The effectiveness of over 20,238 skincare ingredients.
- Information about over 100,000 individual products (luxury, prescription, generic, etc.).
- Over 20 million testimonials from real people.
- Over 4,000 scientific publications.
- The water hardness, humidity level, and UV index where you live.
PROVEN currently offers five products personalized to customers’ unique needs. The products include Personalized Cleaner, Personalized Day Moisturizer, Personalized Night Cream, Personalized Day Eye Cream, and Personalized Night Eye Cream. The products can be conveniently purchased as systems or purchased separately.
PROVEN has only been available in the United States and Canada until this expansion.
About PROVEN
PROVEN is a technology company that harnesses the power of big data and AI to create personalized skincare products. At PROVEN we are building a global self-care movement based on technology and personalization. Through our proprietary Skin Genome Project™ — the largest beauty database on earth — we’ve analyzed over 25 million consumer testimonials and 4,000 skin-related scientific papers to create simple, personalized, and clinically-proven skincare products. PROVEN is a Y Combinator alum and 2018 MIT AI Technology Award recipient. Learn more at www.provenskincare.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220719005333/en/
Contact information
J. Halpin
press@provenskincare.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom